Risk factor
Low price volatility
Profitability factor
Greatly overvalued vs peers
About
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, as well as reproductive medicine services, including assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates four multi-specialty hospitals, including three under the HCG brand in Ahmedabad, Bhavnagar, and Rajkot in the state of Gujarat, as well as one under operations and management contract in Hubli in the state of Karnataka that primarily provide cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, and pulmonary and critical care. In addition, the company offers medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector. As of March 31, 2021, it operated 23 cancer centers, including 1 center of excellence in Bengaluru, 2 freestanding diagnostic centers, and 1 day care chemotherapy center across India, as well as 1 cancer center in Africa. The company was founded in 1989 and is based in Bengaluru, India.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/
Target Price
The average target price of HCG.NS is 694 and suggests 22% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
